Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Item does not contain fulltex

Comment on published paper (Proctor et al, this issue pp 1246-1251).

Contains fulltext : 21728___.PDF (publisher's version ) (Open Access

New treatment approaches for myelodysplastic syndromes

Item does not contain fulltex

Stem Cell transplantation (SCT) for MDS.

Item does not contain fulltex

Autologous stem cell transplantation: introduction.

Item does not contain fulltex

Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?

Contains fulltext : 95637.pdf (publisher's version ) (Closed access)Allogeneic stem cell transplantation (SCT) is the treatment of choice for young patients (age </= 55 years) with myelodysplastic syndromes (MDS) characterized by poor-risk or intermediate-risk cytogenetics, who have a histocompatible related or unrelated donor. For patients who lack an human leukocyte antigen-compatible donor, autologous SCT, or chemotherapy may be good alternatives for those with MDS and with good-risk cytogenetic characteristics. Iron toxicity is an underestimated cause of hematopoietic stem cell transplantation (HSCT) treatment-related mortality. The pathogenesis, diagnosis, and monitoring of iron-induced organ damage are currently topics of investigation. Prospective studies on the prevention or treatment of iron toxicity before HSCT and/or after HSCT are necessary

Myelofibrosis voorbij janus.

Contains fulltext : 79828.pdf (publisher's version ) (Closed access